MODD VS NRXP Stock Comparison

Performance

MODD
10/100

MODD returned -66.69% in the last 12 months. Based on SPY's performance of -13.85%, its performance is below average giving it a score of 10 of 100.

NRXP
10/100

NRXP returned -62.74% in the last 12 months. Based on SPY's performance of -21.23%, its performance is below average giving it a score of 10 of 100.

Technicals

MODD
29/100

MODD receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

NRXP
64/100

NRXP receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

MODD
21/100

MODD has missed earnings 3 times in the last 20 quarters.

NRXP
49/100

NRXP has missed earnings 2 times in the last 20 quarters.

Profit

MODD
10/100

Out of the last 20 quarters, MODD has had 0 profitable quarters and has increased their profits year over year on 0 of them.

NRXP
19/100

Out of the last 20 quarters, NRXP has had 6 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

MODD
41/100

MODD has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

NRXP
41/100

NRXP has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Sentiment

MODD

"Sentiment" not found for MODD

NRXP
69/100

NRXP had a bullish sentiment score of 69.38% across Twitter and StockTwits over the last 12 months. It had an average of 26.28 posts, 15.67 comments, and 77.44 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Modular Medical, Inc. Common Stock Summary

Nasdaq / MODD

Healthcare

Medical - Devices

Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.

NRX Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / NRXP

Healthcare

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Power up your portfolio